Plain-English translation of NCT05147701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) to treat non-arteritic ischemic optic neuropathy, a condition where the optic nerve doesn't get enough blood flow, causing vision loss. The treatment involves injecting 100 million of these stem cells directly into or around the eye using two different methods. Researchers will monitor participants for up to 4 years to see if the treatment is safe and whether it helps restore vision.
Currently, there are very few effective treatments for optic nerve damage from poor blood flow. This trial exists to explore whether stem cells—which have unique healing properties—might be able to repair damaged nerve tissue and restore vision in patients who have limited options otherwise.
You likely qualify if…
You likely don't qualify if…
You will receive two injections of stem cells—one through an IV and one directly into the tissue around your eye. You'll have an initial evaluation visit about a month before treatment, then return for follow-up appointments at 1 month, 6 months, 1 year, 2 years, 3 years, and 4 years after treatment. These visits will include eye exams and safety monitoring to track how you're doing.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Antigua and Barbuda
Argentina
Phase
Safety & dosing
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment target
~20 participants
Started
February 2022
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.